A Phase II, Open-Label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Senl_B19 Autologous Anti-CD19 CAR-T Cells in Subjects With Relapsed or Refractory CD19-Positive B-Cell Acute Lymphoblastic Leukemia

Study Summary

To evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL.

Interventions

Study Locations

Facility	City	State	Country
Peking University People's Hospital	Beijing		China

Official Trial Information

View on ClinicalTrials.gov